I-Mab Stock Price, News & Analysis

I-Mab, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IMAB, is set to host its 2022 Research and Development (R&D) Day on July 20, 2022. The event will feature presentations from key executives including Dr. Jingwu Zang and Dr. Andrew Zhu, focusing on the company's innovative assets and clinical development strategies. The Mandarin session begins at 9:00 am CST, while the English session starts at 8:00 am EST. Interested participants can find registration links for both sessions in the official announcement.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, received top rankings in five categories from Institutional Investor in its 2022 All-Asia Executive Team survey. The awards included 'Best CEO' for Dr. Jingwu Zang and 'Best CFO' for John Long, highlighting the company's leadership, corporate governance, and ESG strategy. This marks I-Mab's second consecutive year as the 'Honored Company' in healthcare. The recognition underscores I-Mab's commitment to innovation and value creation, affirming its trajectory as a competitive player in the biopharmaceutical sector.

I-Mab (Nasdaq: IMAB) announced the advancement of two assets through new licensing agreements with MorphoSys AG (FSE: MOR). The agreements grant Human Immunology Biosciences, Inc. exclusive rights to develop and commercialize felzartamab and TJ210 outside Greater China. Felzartamab is in registrational trials for multiple myeloma in China, while TJ210 is undergoing Phase 1 trials in the U.S. These developments enhance I-Mab's position in the biopharmaceutical sector and aim to expedite the availability of innovative therapies to patients.

I-Mab (Nasdaq: IMAB) announced new licensing agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR) for felzartamab (TJ202/MOR202) and TJ210 (MOR210). HIBio will develop and commercialize these antibodies outside Greater China and South Korea. I-Mab retains exclusive rights for felzartamab in Greater China, having made significant progress toward its registration. The agreements aim to advance clinical development and commercialization, with ongoing trials for both products in different regions. These initiatives reflect I-Mab's strategy to expand its innovative drug pipeline globally.

MorphoSys and Human Immunology Biosciences (HIBio) have entered into agreements for HIBio to develop and commercialize the monoclonal antibodies felzartamab and MOR210. MorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments, plus royalties. This partnership allows MorphoSys to concentrate on advancing its oncology pipeline, including potential best-in-class treatments. HIBio holds exclusive rights for these antibodies globally, except in specified regions.

Genexine has announced that its partner, I-Mab, completed patient enrollment in a phase 3 clinical trial of eftansomatropin alfa (GX-H9/TJ101) in China. This long-acting growth hormone aims to treat pediatric growth hormone deficiency (PGHD) and is compared to Norditropin® in a study involving 168 patients. This milestone is pivotal for commercialization in a significant market. Final data from the study is expected in 2023, with a potential Biologics License Application to follow. Eftansomatropin alfa could offer advantages over traditional therapies due to its unique formulation.

Ferring Pharmaceuticals has entered a strategic collaboration with I-Mab to further develop olamkicept for inflammatory bowel disease (IBD). Olamkicept is the first clinical-stage selective interleukin-6 (IL-6) inhibitor utilizing a trans-signaling mechanism. Positive Phase 2 study results for olamkicept in ulcerative colitis were presented at the 2021 ECCO meeting. This collaboration offers I-Mab options for future development milestones while Ferring expands olamkicept's global development. Financial terms of the agreement remain undisclosed.

Genexine announced results from the KEYNOTE-899 phase 1b/2 clinical trial of GX-I7 (efineptakin alfa) with pembrolizumab. The trial demonstrated safety and early anti-tumor activity in patients with R/R metastatic TNBC. Overall response rates (ORR) were 15.7% in phase 1b and 21.2% in phase 2, with a notable 60% ORR in PD-L1 positive patients. CEO Neil Warma highlighted the potential of GX-I7 as a first-in-class treatment. Genexine is focusing on global development in multiple cancers with partners NeoImmune Tech and I-Mab.

I-Mab (Nasdaq: IMAB) has completed patient enrollment in the Phase 3 TALLER clinical trial for eftansomatropin alfa (TJ101), targeting pediatric growth hormone deficiency (PGHD) in China. The study enrolled 168 patients and aims to assess the efficacy and safety of the long-acting growth hormone compared to daily alternatives. Final data is expected in 2023, followed by a Biologics License Application submission. The company is collaborating with Jumpcan Pharmaceutical Group to expedite the commercialization of this novel therapy, addressing a significant unmet need in PGHD treatment.